Novel and Emerging Targeted Therapies of Colorectal Cancer

被引：4
作者：
Finnberg, Niklas [1 ,2 ]
Gokare, Prashanth
El-Deiry, Wafik S.
机构：
[1] Fox Chase Canc Ctr, Lab Translat Oncol & Expt Canc Therapeut, Dept Med Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[2] Fox Chase Canc Ctr, Mol Therapeut Program, Philadelphia, PA 19111 USA
来源：
CURRENT CLINICAL PHARMACOLOGY | 2015年 / 10卷 / 04期
关键词：
Clinical; colorectal cancer; DPYD; RAS; targeted therapy; TRAIL;
D O I：
10.2174/1574884710666151020095911
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The survival rate of patients with colorectal cancer (CRC) is steadily increasing over the past decade. However, CRC continue to be one of the leading causes of cancer-related fatality in the United States. Current targeted strategies offer limited clinical benefits and the overall survival rate for CRC remains low. Improved understanding of the molecular changes associated with CRC that control growth factor signaling and evasion of cell death allow for the development of improved targeted therapy. This review aims to discuss some of the emerging therapies aimed to target CRC.
引用
收藏
页码：279 / 298
页数：20
相关论文
共 242 条
[1]   TRAIL receptor signaling and therapeutics [J].
Abdulghani, Junaid ;
El-Deiry, Wafik S. .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2010, 14 (10) :1091-1108
[2]  
Ahnen DJ, 1998, CANCER RES, V58, P1149
[3]  
Al Olayan Ashwaq, 2012, J Infect Public Health, V5 Suppl 1, pS50, DOI 10.1016/j.jiph.2012.09.004
[4]   Circulating Tumor Cells and Colorectal Cancer [J].
Allen, Joshua E. ;
El-Deiry, Wafik S. .
CURRENT COLORECTAL CANCER REPORTS, 2010, 6 (04) :212-220
[5]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[6]  
American Cancer Society, 2015, CANC FACTS FIG 2015
[7]   CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors [J].
Anderson, Victoria E. ;
Walton, Michael I. ;
Eve, Paul D. ;
Boxall, Katherine J. ;
Antoni, Laurent ;
Caldwell, John J. ;
Aherne, Wynne ;
Pearl, Laurence H. ;
Oliver, Antony W. ;
Collins, Ian ;
Garrett, Michelle D. .
CANCER RESEARCH, 2011, 71 (02) :463-472
[8]   CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? [J].
Antoni, Laurent ;
Sodha, Nayanta ;
Collins, Ian ;
Garrett, Michelle D. .
NATURE REVIEWS CANCER, 2007, 7 (12) :925-936
[9]   Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles [J].
Arienti, KL ;
Brunmark, A ;
Axe, FU ;
McClure, K ;
Lee, A ;
Blevitt, J ;
Neff, DK ;
Huang, LM ;
Crawford, S ;
Pandit, CR ;
Karlsson, L ;
Breitenbucher, JG .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (06) :1873-1885
[10]   Potentiation of the Novel Topoisomerase I Inhibitor Indenoisoquinoline LMP-400 by the Cell Checkpoint and Chk1-Chk2 Inhibitor AZD7762 [J].
Aris, Sheena M. ;
Pommier, Yves .
CANCER RESEARCH, 2012, 72 (04) :979-989
12345678910